KISUMU, Kenya – Cancer patients can breathe a sigh of relief after the Amulet Sophinity digital mammography system, a cutting-edge AI-enabled device that greatly improves breast cancer screening and diagnosis, was deployed at Jaramogi Oginga Odinga Teaching and Referral Hospital (JOOTRH).
The new approach is intended to assist high-risk adults, both men and women, who are 40 years of age or older and who are referred for examination by physicians. However, screening can start as early as age 35 for people with a family history of cancer, enabling early discovery and prompt treatment.
Digital Breast Tomosynthesis (DBT), a 3D imaging technique that uses low-dose X-rays to create high-resolution images, is a part of the Amulet Sophinity system. Compared to traditional techniques, it makes it possible to detect minor anomalies in breast tissue, such as malignant and diseased cells, much more successfully.
The system provides rapid image capture, realistic magnification for up-close viewing, and improved comfort even during compression. To ensure that no one is left behind in screening efforts, the machine can also be adjusted to lower heights—up to 50 cm—making it wheelchair accessible.
In addition to initial screening, the method is essential for monitoring the course of treatment, including whether a tumour is decreasing following radiation or chemotherapy.
Following installation, 15 people 40 years of age and older received complimentary mammography screenings from JOOTRH. The service is currently offered for a reasonable price of Sh1,500.
In March 2024, JOOTRH received an innovative Prostate Cancer Machine. Area Governor Prof. Peter Anyang’ Nyong’o urged men to take charge of their health during the unveiling of a new ultrasound-guided prostate biopsy machine at JOOTRH.
The machine, donated by AstraZeneca in partnership with Cancer Care Africa, offers a more accurate and private way to diagnose prostate cancer.
“This machine is more than just equipment. It’s a symbol of progress,” Governor Nyong’o said. “With it, we empower men to take control of their health, lighten the burden on our healthcare system, and build a brighter future where prostate cancer is no longer a silent threat,” said Governor Nyong’o.
Benefits of the New Machine
- Governor Nyong’o highlighted several benefits of the new machine:
- Increased Accuracy: Ultrasound-guided biopsies improve diagnosis, leading to better treatment decisions.
- Reduced Cost: Early detection saves lives and reduces overall treatment costs.
- Improved Outcomes: Early treatment leads to better patient outcomes and a higher chance of successful treatment.
- The machine provides free prostate cancer diagnosis at JOOTRH, removing the economic burden for patients (diagnosis typically costs between Sh70,000 and Sh200,000).
Collaboration for Better Healthcare
The governor commended the collaboration between JOOTRH, Cancer Care Africa, and AstraZeneca. He also urged men in Kenya to be proactive about their health by getting screened for prostate cancer.
Studies show that about 78% of men in Kenya present with advanced prostate cancer when first diagnosed. JOOTRH’s oncology and urology clinics see about 40 to 50 patients every month, most of whom cannot afford ultrasound-guided biopsies.
The donation will shorten wait times for diagnosis, reduce the financial burden on patients, and improve the treatment pathway for prostate cancer patients at JOOTRH.
Continued Support for Cancer Care
Dr. Ellias Melly, CEO of the National Cancer Institute, pledged continuous support in fighting cancer. He emphasised the importance of collaboration between various stakeholders.
On the other hand, Dr. Greggory Ganda, County Executive Committee member for medical, public health, and sanitation, announced plans to establish 35 wellness centres across all wards in Kisumu County to facilitate early cancer diagnosis.
In addition to the machine, JOOTRH staff, including urologists, pathologists, oncologists, and radiologists, received training at Cairo University in Egypt in 2023 as part of the collaboration between CCA and AstraZeneca. The collaboration also provided mentorship courses in prostate biopsies and support for access to prostate cancer treatment medications.
